Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation.
By J. Milano, J. McKay, C. Dagenais, L. Foster-Brown, F. Pognan, R. Gadient, R. Jacobs, A. Zacco, B. Greenberg, P. Ciaccio. Toxicological Sciences, 2004
609 citations recorded by the source corpus.
Subfields: Cellular and Molecular Neuroscience, Genetics, Surgery
View Paper: https://www.semanticscholar.org/paper/afb38d9cf659dff6f6ed876bbc0110fbb82aa3aa
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cellular and Molecular Neuroscience
In Genetics
- Hans Clevers
- H. Begthel
- Toshiro Sato
- M. van de Wetering
- Martin Citron
- Nick Barker
- R. Nusse
- Pengfei Lu
In Surgery
Citations in the corpus
- The intestinal crypt, a prototype stem cell compartment. (2013, background): “Inhibition of Notch signaling in the intestinal epithelium (either genetically by conditional deletion of CSL or pharmacologically by g-secretase inhibitors) results in the conversion of all proliferative cells into goblet cells (Milano et al., 2004; van Es et al., 2005b).”
- Alzheimer's disease: strategies for disease modification (2010, background): “Studies with several structurally different γ-secretase inhibitors at high doses have shown that inhibition of Notch1 cleavage blocks thymocyte differentiation and splenic B-cell maturation, and causes intestinal goblet-cell metaplasia in adult animal”
- Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis (2013, positive): “We included the small molecule inhibitor ILV combined with FGF10, to induce Pdx1 expression (Bhushan et al , 2001; Chen et al , 2009), followed by DBZ treatment, to inhibit notch signalling (Milano et al , 2004) (Supplementary Figure S9A).”